Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 2/20 | 0.53 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741057 | 0.83 | PIN1 (0.56) | PIN1POLBCDC7DBF4CYP1A2 | |
| SCHEMBL21385377 | 0.81 | CYP1A2 (0.66) | POLBCDC7DBF4CYP1A2CYP3A4 | |
| SCHEMBL15759317 | 0.80 | PIN1 (0.64) | PIN1POLBCDC7DBF4CYP1A2 | |
| Chloroform SCHEMBL743258 | 0.80 | PIN1 (0.53) | PIN1POLBCDC7DBF4CYP1A2 | |
| SCHEMBL3002688 | 0.79 | POLB (0.52) | PIN1POLBCDC7DBF4HPGD | |
| SCHEMBL5998044 | 0.78 | ADORA3 (0.55) | PIN1POLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2996508 | 0.78 | HSD17B10 (0.45) | PIN1POLBCDC7DBF4CYP1A2 | |
| SCHEMBL16146158 | 0.75 | PDE4A (0.64) | PIN1POLBCDC7DBF4CYP1A2 | |
| SCHEMBL3907002 | 0.75 | CDK1 (0.48) | PIN1POLBCDC7DBF4CYP1A2 | |
| SCHEMBL30578627 | 0.74 | POLB (0.49) | PIN1POLBCDC7DBF4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-11-05 | — | — | US | disclosed |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-24 | — | — | US | disclosed |
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2019-09-03 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-28 | — | — | US | disclosed |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-14 | — | — | US | disclosed |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-14 | — | — | US | disclosed |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-07 | — | — | US | disclosed |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-04-07 | — | — | US | disclosed |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) | 2016-01-07 | — | — | US | disclosed |
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-0423805-B1 | Condensed purine derivatives | KYOWA HAKKO KOGYO KK (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0601092-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | Novartis AG (CH) | 1994-06-15 | — | — | EP | disclosed |
| US-5270316-A | Condensed purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-12-14 | — | — | US | disclosed |
| WO-1993005163-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |
| EP-0423805-A2 | Condensed purine derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398665-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TMEM120A | PIN1 3856/4885POLB 2912/4885CDC7 4577/4885 |
| US-10420738-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | PIN1 3094/4885POLB 2603/4885CDC7 4184/4885 |
| US-20160101107-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TCOF1 | PIN1 3094/4885POLB 2603/4885CDC7 4184/4885 |
| US-20160113896-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TCOF1 | PIN1 3094/4885POLB 2603/4885CDC7 4184/4885 |
| US-20160095869-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TMEM120A | PIN1 3856/4885POLB 2912/4885CDC7 4577/4885 |
| US-10463639-B2 | Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction | CFTR, TMEM161A, TCOF1 | PIN1 3094/4885POLB 2603/4885CDC7 4184/4885 |
| US-20160000778-A1 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION | CFTR, TMEM161A, TMEM120A | PIN1 3856/4885POLB 2912/4885CDC7 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.